The discovery of effective disease treatments has slowed. This may be related to a misunderstanding of the treatment-discovery process, and an underappreciation of clinical investigations and off-label drug studies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
A full listing of biotechnology drugs is available from the authors.
Williams, G.H. An Analysis of the Review of Patient-Oriented Research(PR) Grant Applications by the Division of Research Grants, NIH (Clinical Research Study Group, NIH, 1994).
Kelly, W.M. and Randolph, M.A. Careers in Clinical Research: Obstacles and Opportunities (National Academy Press, Washington, 1994).
Jobe, P.C. et al. The essential role of integrative biomedical sciences in protecting and contributing to the health and well-being of our nation. The Physiologist 37, 79–84 (1994).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wurtman, R., Bettiker, R. The slowing of treatment discovery, 1965–1995. Nat Med 1, 1122–1125 (1995). https://doi.org/10.1038/nm1195-1122
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1195-1122
This article is cited by
-
Diagnosing the decline in pharmaceutical R&D efficiency
Nature Reviews Drug Discovery (2012)
-
Pharmaceutical Medicine Teaching Syllabus for Medical Writers
Pharmaceutical Medicine (2010)
-
Can intellectualism stifle scientific discovery?
Nature Reviews Drug Discovery (2002)
-
Clinical research, or classical clinical research?
Nature Medicine (1999)
-
Discoveries in complex biosystems
Nature Biotechnology (1997)
